Lilly's ulcerative colitis treatment Omvoh (mirikizumab-mrkz) is nearing approval in Korea.

Omvoh received U.S. FDA approval in October last year and settled as the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

According to industry sources, the Ministry of Food and Drug Safety recently completed a safety and efficacy review for Omvoh’s marketing authorization in Korea. MFDS’ completion of the safety and efficacy review means that marketing authorization for the drug is imminent.

Omvoh is the only ulcerative colitis treatment that selectively binds to the p19 subunit of IL-we a